Wanbangde Pharmaceutical Holding Group Co Ltd Cash Flow-to-Debt Ratio
Wanbangde Pharmaceutical Holding Group Co Ltd cash flow-to-debt ratio. Wanbangde Pharmaceutical Holding Group Co Ltd (002082) has a Cash Flow-to-Debt Ratio of 0.00x as of September 2025, meaning its operating cash flow of CN¥-1.04 Million could theoretically repay 0% of its total liabilities (CN¥1.78 Billion) in one year. Check 002082 cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Wanbangde Pharmaceutical Holding Group Co Ltd (2003–2025)
Cash flow-to-debt ratio of Wanbangde Pharmaceutical Holding Group Co Ltd from 2003 to 2025. Historical debt coverage capacity for Wanbangde Pharmaceutical Holding Group Co Ltd across 23 annual periods. Check earnings quality score of Wanbangde Pharmaceutical Holding Group C to evaluate the quality of earnings relative to operating cash generation.
Wanbangde Pharmaceutical Holding Group Co Ltd Cash Flow-to-Debt Ratio by Year (2003–2025)
Wanbangde Pharmaceutical Holding Group Co Ltd cash flow-to-debt ratio by year from 2003 to 2025. Year-by-year debt coverage analysis for Wanbangde Pharmaceutical Holding Group Co Ltd. For the full cash flow conversion analysis, see Wanbangde Pharmaceutical Holding Group C cash flow conversion.
| Year | CF-to-Debt Ratio | Operating CF (CNY) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.34x | CN¥603.98 Million | CN¥1.78 Billion | ▲ +342.5% |
| 2024 | 0.08x | CN¥120.22 Million | CN¥1.57 Billion | ▲ +261.5% |
| 2023 | -0.05x | CN¥-72.87 Million | CN¥1.54 Billion | ▲ +72.4% |
| 2022 | -0.17x | CN¥-239.65 Million | CN¥1.40 Billion | ▼ -1364.0% |
| 2021 | 0.01x | CN¥22.09 Million | CN¥1.63 Billion | ▼ -74.8% |
| 2020 | 0.05x | CN¥151.01 Million | CN¥2.80 Billion | ▲ +140.9% |
| 2019 | -0.13x | CN¥-248.69 Million | CN¥1.89 Billion | ▼ -209.1% |
| 2018 | 0.12x | CN¥135.40 Million | CN¥1.12 Billion | ▲ +440.5% |
| 2017 | -0.04x | CN¥-17.60 Million | CN¥496.58 Million | ▼ -103.0% |
| 2016 | 1.19x | CN¥310.71 Million | CN¥261.85 Million | ▲ +1813.3% |
| 2015 | 0.06x | CN¥16.76 Million | CN¥270.28 Million | ▼ -88.7% |
| 2014 | 0.55x | CN¥140.31 Million | CN¥254.69 Million | ▼ -15.1% |
| 2013 | 0.65x | CN¥234.35 Million | CN¥361.07 Million | ▲ +50.2% |
| 2012 | 0.43x | CN¥202.73 Million | CN¥469.09 Million | ▲ +11897.2% |
| 2011 | 0.00x | CN¥-1.44 Million | CN¥392.22 Million | ▼ -100.9% |
| 2010 | 0.43x | CN¥162.26 Million | CN¥380.46 Million | ▲ +92.4% |
| 2009 | 0.22x | CN¥68.13 Million | CN¥307.39 Million | ▼ -72.9% |
| 2008 | 0.82x | CN¥253.06 Million | CN¥309.46 Million | ▲ +3265.4% |
| 2007 | 0.02x | CN¥12.45 Million | CN¥512.51 Million | ▲ +242.8% |
| 2006 | 0.01x | CN¥3.50 Million | CN¥493.85 Million | ▼ -67.9% |
| 2005 | 0.02x | CN¥11.23 Million | CN¥508.84 Million | ▼ -81.1% |
| 2004 | 0.12x | CN¥32.69 Million | CN¥280.48 Million | ▼ -48.7% |
| 2003 | 0.23x | CN¥37.01 Million | CN¥163.05 Million | — |